Vaxcyte Current Deferred Revenue vs Long Term Debt Analysis

PCVX Stock  USD 91.70  3.16  3.57%   
Vaxcyte financial indicator trend analysis is much more than just breaking down Vaxcyte prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vaxcyte is a good investment. Please check the relationship between Vaxcyte Current Deferred Revenue and its Long Term Debt accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Vaxcyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Current Deferred Revenue vs Long Term Debt

Current Deferred Revenue vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vaxcyte Current Deferred Revenue account and Long Term Debt. At this time, the significance of the direction appears to have totally related.
The correlation between Vaxcyte's Current Deferred Revenue and Long Term Debt is 1.0. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Vaxcyte, assuming nothing else is changed. The correlation between historical values of Vaxcyte's Current Deferred Revenue and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Vaxcyte are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Current Deferred Revenue i.e., Vaxcyte's Current Deferred Revenue and Long Term Debt go up and down completely randomly.

Correlation Coefficient

1.0
Relationship DirectionPositive 
Relationship StrengthVery Strong

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Long Term Debt

Long-term debt is a debt that Vaxcyte has held for over one year. Long-term debt appears on Vaxcyte balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Vaxcyte balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.
Most indicators from Vaxcyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vaxcyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Vaxcyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.Selling General Administrative is likely to rise to about 63.7 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 364.6 M in 2024.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization1.8M9.2M3.2M4.0M
Net Interest Income337K8.4M62.9M66.1M

Vaxcyte fundamental ratios Correlations

0.920.950.99-0.940.99-0.990.540.730.2-0.730.990.86-0.730.880.521.00.960.870.850.94-0.67-0.760.930.910.76
0.920.990.9-0.790.87-0.940.450.44-0.12-0.60.880.78-0.60.740.580.880.840.760.730.98-0.53-0.480.990.990.58
0.950.990.93-0.850.91-0.960.560.53-0.04-0.680.920.82-0.680.830.560.920.90.790.80.97-0.61-0.560.970.970.68
0.990.90.93-0.961.0-0.980.540.750.23-0.690.990.84-0.690.890.420.990.970.880.860.92-0.64-0.780.910.890.77
-0.94-0.79-0.85-0.96-0.970.93-0.6-0.81-0.440.74-0.96-0.840.74-0.95-0.36-0.96-0.98-0.92-0.92-0.840.70.82-0.81-0.77-0.88
0.990.870.911.0-0.97-0.970.570.80.3-0.741.00.86-0.740.910.441.00.980.890.880.9-0.69-0.820.880.850.81
-0.99-0.94-0.96-0.980.93-0.97-0.51-0.66-0.190.75-0.97-0.890.75-0.88-0.57-0.97-0.96-0.9-0.86-0.970.690.68-0.95-0.93-0.76
0.540.450.560.54-0.60.57-0.510.620.11-0.70.570.63-0.70.740.30.570.660.360.720.37-0.69-0.610.370.360.77
0.730.440.530.75-0.810.8-0.660.620.53-0.670.80.71-0.670.740.30.80.770.610.720.46-0.67-0.990.430.390.76
0.2-0.12-0.040.23-0.440.3-0.190.110.53-0.460.260.31-0.460.45-0.020.260.370.530.370.04-0.5-0.48-0.04-0.120.55
-0.73-0.6-0.68-0.690.74-0.740.75-0.7-0.67-0.46-0.74-0.861.0-0.86-0.63-0.75-0.83-0.74-0.75-0.621.00.65-0.59-0.55-0.84
0.990.880.920.99-0.961.0-0.970.570.80.26-0.740.87-0.740.890.51.00.970.860.850.9-0.69-0.820.880.860.78
0.860.780.820.84-0.840.86-0.890.630.710.31-0.860.87-0.860.860.670.870.890.810.910.79-0.84-0.680.770.740.87
-0.73-0.6-0.68-0.690.74-0.740.75-0.7-0.67-0.461.0-0.74-0.86-0.86-0.63-0.75-0.83-0.74-0.75-0.621.00.65-0.59-0.55-0.84
0.880.740.830.89-0.950.91-0.880.740.740.45-0.860.890.86-0.860.40.890.970.890.930.79-0.84-0.740.750.710.95
0.520.580.560.42-0.360.44-0.570.30.3-0.02-0.630.50.67-0.630.40.50.460.410.410.53-0.6-0.260.540.540.37
1.00.880.920.99-0.961.0-0.970.570.80.26-0.751.00.87-0.750.890.50.970.870.860.9-0.7-0.820.880.860.78
0.960.840.90.97-0.980.98-0.960.660.770.37-0.830.970.89-0.830.970.460.970.910.920.88-0.79-0.780.850.820.89
0.870.760.790.88-0.920.89-0.90.360.610.53-0.740.860.81-0.740.890.410.870.910.830.87-0.71-0.610.820.770.8
0.850.730.80.86-0.920.88-0.860.720.720.37-0.750.850.91-0.750.930.410.860.920.830.77-0.72-0.70.740.710.96
0.940.980.970.92-0.840.9-0.970.370.460.04-0.620.90.79-0.620.790.530.90.880.870.77-0.55-0.491.00.990.63
-0.67-0.53-0.61-0.640.7-0.690.69-0.69-0.67-0.51.0-0.69-0.841.0-0.84-0.6-0.7-0.79-0.71-0.72-0.550.64-0.52-0.47-0.84
-0.76-0.48-0.56-0.780.82-0.820.68-0.61-0.99-0.480.65-0.82-0.680.65-0.74-0.26-0.82-0.78-0.61-0.7-0.490.64-0.46-0.43-0.73
0.930.990.970.91-0.810.88-0.950.370.43-0.04-0.590.880.77-0.590.750.540.880.850.820.741.0-0.52-0.461.00.59
0.910.990.970.89-0.770.85-0.930.360.39-0.12-0.550.860.74-0.550.710.540.860.820.770.710.99-0.47-0.431.00.54
0.760.580.680.77-0.880.81-0.760.770.760.55-0.840.780.87-0.840.950.370.780.890.80.960.63-0.84-0.730.590.54
Click cells to compare fundamentals

Vaxcyte Account Relationship Matchups

Vaxcyte fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets65.7M392.8M324.3M1.0B1.4B1.5B
Other Current Liab7.5M17.1M11.4M18.9M116.5M122.4M
Total Current Liabilities11.1M46.9M28.7M40.5M145.3M152.6M
Total Stockholder Equity(106.4M)345.8M284.0M953.6M1.2B1.3B
Other Liab259K122K96K9K8.1K7.7K
Net Tangible Assets(106.4M)345.8M284.0M953.6M1.1B1.2B
Retained Earnings(109.3M)(198.6M)(298.6M)(522.1M)(924.4M)(878.2M)
Accounts Payable3.4M29.8M6.8M9.8M14.6M10.8M
Cash59.0M386.2M69.0M834.7M397.5M290.5M
Other Assets584K550K5.0M5.4M1.00.95
Cash And Short Term Investments59.0M386.2M246.0M931.4M1.1B1.1B
Common Stock Shares Outstanding48.9M51.1M51.9M64.9M97.2M57.4M
Capital Surpluse1.3M3.0M544.4M582.8M670.3M703.8M
Total Liab172.1M47.0M40.3M52.6M167.4M96.9M
Total Current Assets61.7M389.0M256.3M942.6M1.1B1.2B
Common Stock7K54K56K82K98K102.9K
Property Plant Equipment3.4M3.3M35.9M31.6M36.4M38.2M
Property Plant And Equipment Net3.4M3.3M35.9M31.6M110.6M116.2M
Net Debt(58.8M)(386.2M)(52.2M)(816.7M)(368.2M)(386.6M)
Non Current Assets Total4.0M3.8M68.0M63.6M312.0M327.6M
Non Currrent Assets Other584K550K5.0M5.4M38.7M40.6M
Liabilities And Stockholders Equity65.7M392.8M324.3M1.0B1.4B1.5B
Non Current Liabilities Total161.0M122K11.6M12.0M22.1M43.8M
Capital Lease Obligations161K0.016.8M17.9M29.2M30.7M
Other Current Assets2.7M2.5M9.2M5.3M15.7M16.5M
Other Stockholder Equity3.0M151.5M582.8M1.5B2.2B2.3B
Net Invested Capital(106.4M)345.8M284.0M953.6M1.2B1.3B
Accumulated Other Comprehensive Income(160.3M)(392.8M)(241K)(361K)179K188.0K
Capital Stock7K54K56K82K98K55.6K
Non Current Liabilities Other242K112K96K9K8.1K7.7K
Net Working Capital50.7M342.1M227.6M902.0M950.6M998.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.